GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was £10.25B, up 55.9% from the year before. Over ten years it grew -1.5% a year on average. The highest annual figure on record is £11.95B in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £10.25B | +55.9% |
| FY2024 | Dec 31, 2024 | £6.57B | -27.3% |
| FY2023 | Dec 31, 2023 | £9.04B | +5.3% |
| FY2022 | Dec 31, 2022 | £8.58B | +32.4% |
| FY2021 | Dec 31, 2021 | £6.48B | -19.3% |
| FY2020 | Dec 31, 2020 | £8.03B | -13.6% |
| FY2019 | Dec 31, 2019 | £9.30B | +26.7% |
| FY2018 | Dec 31, 2018 | £7.34B | +22.1% |
| FY2017 | Dec 31, 2017 | £6.01B | +37.4% |
| FY2016 | Dec 31, 2016 | £4.37B | -63.4% |
| FY2015 | Dec 31, 2015 | £11.95B | – |